Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switching Antipsychotics May Not Be Best Option, New CATIE Analysis Finds

Executive Summary

Ongoing analyses of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) continue to support a benefit for Lilly's Zyprexa over other antipsychotic medications, with the latest trial results showing that Zyprexa is the only atypical where patients did better by remaining on the drug
Advertisement

Related Content

CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge
Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Advertisement
UsernamePublicRestriction

Register

PS047835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel